Balanced news tone
News Sentiment
TNGX sentiment intelligence
Tango Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
83/100 classification confidence.
directly relevant articles
high-authority source matches
-8.0% over one week, +2.1% over four weeks, trend active, and materially above fair value.
Mizuho Raises Price Target on Tango Therapeutics to $40 From $36, Keeps Outperform Rating
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Director at Tango Therapeutics (TNGX) receives RSUs and stock options
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 07:00
- Source
- Stock Titan
Tango Therapeutics Appoints Robert Azelby to Board of Directors
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 20:05
- Source
- GlobeNewswire
TNGX (Nasdaq: TNGX) affiliate files Form 144 to sell 3.5M shares
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 17 Jun 2026 07:00
- Source
- Stock Titan
[144] Tango Therapeutics, Inc. SEC Filing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jun 2026 07:00
- Source
- Stock Titan
Has Tango Therapeutics (TNGX) Run Too Far After Recent Price Surge?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 10 Jun 2026 07:00
- Source
- simplywall.st
Is Tango Therapeutics (TNGX) Price Justified After Its 7x Surge In One Year
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 10 Jun 2026 07:00
- Source
- Market source
Tango Therapeutics (NASDAQ: TNGX) prices $566.5M stock and warrant offering
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jun 2026 07:00
- Source
- Stock Titan
Insider sale notice — TNGX (NASDAQ:TNGX) reports planned share sales
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jun 2026 07:00
- Source
- Stock Titan
Tango Therapeutics stock rockets 53% on pancreatic cancer data
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jun 2026 07:00
- Source
- grafa.com
Tango Therapeutics (TNGX) Stock Soars on Pancreatic Cancer Trial Results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 09 Jun 2026 07:00
- Source
- Market source
Cancer drug developer Tango Therapeutics seeks $500M in stock sale
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jun 2026 07:00
- Source
- Stock Titan
Tango Therapeutics Announces Proposed $500 Million Public Offering
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jun 2026 07:00
- Source
- GlobeNewswire
TNGX Stock Hits All-Time High – Wolfe Research Calls Tango Therapeutic’s Pancreatic Cancer Trial Data ‘Groundbreaking’
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jun 2026 07:00
- Source
- Market source
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 May 2026 07:00
- Source
- Market source
Tango Therapeutics (TNGX) Is Down 10.7% After Pipeline Pivot And Board Changes - Has The Bull Case Changed?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 May 2026 07:00
- Source
- Market source
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Stifel and Jefferies Raise Targets on Tango Therapeutics (TNGX)
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 06 Apr 2026 07:00
- Source
- Market source
Tango Therapeutics (TNGX) R&D chief exercises options, sells 12,000 shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Mar 2026 07:00
- Source
- Stock Titan
Tango Therapeutics (TNGX) Valuation Check After Strong Share Price Momentum And High P/S Multiple
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 08 Mar 2026 08:00
- Source
- Market source
Tango Therapeutics Stock Jumps 36% to a New High. Here’s What’s Driving the Move
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Mar 2026 08:00
- Source
- TIKR.com
Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 53% Price Boost Is Out Of Tune With Revenues
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jan 2026 08:00
- Source
- simplywall.st
Tango Therapeutics Announces $225 Million Financing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Oct 2025 07:00
- Source
- GlobeNewswire
Tango Therapeutics Announces Pricing of $210 Million Underwritten Offering and $15 Million PIPE Financing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Oct 2025 07:00
- Source
- Quiver Quantitative
Tango Therapeutics Second Quarter 2025 Earnings: Misses Expectations
- Tone
- Negative 15/100
- Event
- Earnings
- Published
- 06 Aug 2025 07:00
- Source
- simplywall.st